Rituximab biosimilar - LG Life SciencesAlternative Names: LBRx
Latest Information Update: 07 Oct 2013
At a glance
- Originator LG Life Sciences
- Class Antineoplastics; Antirheumatics; Monoclonal antibodies
- Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Rheumatoid arthritis
Most Recent Events
- 31 Jul 2013 Preclinical trials in Rheumatoid arthritis in South Korea (Parenteral)
- 31 Dec 2008 Early research in Rheumatoid arthritis in South Korea (Parenteral)